🇺🇸

Index Intelligence

· daily

S&P 500 Industrials Sector SEC Filings — May 04, 2026

Across 50 SEC filings from the USA S&P 500 Industrials stream (broadly encompassing aerospace, defense, machinery, transportation, construction, and adjacent sectors), overarching themes include mixed Q1 2026 earnings with 6/10 reporting companies showing revenue growth averaging +20% YoY (e.g., Biodesix +42%, Backblaze +11.7%) offset by declines in cyclicals like Boise Cascade (-2% sales YoY) and Cogent (-3.2% YoY), alongside accretive M&A in industrial real estate and positive capital raises/licensing in health-adjacent industrials. EBITDA margins expanded in 7/12 key filers (avg +200bps YoY, driven by cost controls at Boise +136% BMD EBITDA growth and Backblaze +800bps to 26%), signaling operational resilience amid softening demand from housing starts (-5% YoY). Capital allocation remains shareholder-friendly with $65.5M Boise buybacks, $548M Diamondback repurchases, and consistent dividends (e.g., Marzetti $0.12/share). Forward-looking catalysts cluster in Q2-Q3 2026, including merger closes, guidance realizations, and clinical data readouts. Institutional 13F snapshots (16/50 filings) reveal heavy tech/industrials tilts (e.g., Vertiv, BWX Tech), indicating conviction in infrastructure/AI themes. Most critical: Global Net Lease's $535M industrial acquisition (4% AFFO accretive, Q3 close) and Biodesix's 42% revenue surge with raised FY guidance, positioning select industrials for outperformance vs. sector peers.

16 high priority 34 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 04, 2026

S&P 500 Energy sector filings reveal mixed Q1 2026 performance, with ExxonMobil (XOM) posting 2.4% YoY revenue growth to $85.1B but a sharp 45.8% YoY net income drop to $4.2B due to higher costs and Energy Products losses, contrasting Hess Midstream's (HESM) stable results with Adjusted EBITDA up 2.6% YoY to $299.8M. Major M&A advances with Devon Energy (DVN) and Coterra (CTRA) merger overwhelmingly approved (98-99% votes), set to close ~May 7, enhancing scale in E&P. Leadership transitions signal continuity: XOM elects new Chief Accounting Officer effective July 1, Occidental (OXY) names COO Richard Jackson as CEO from June 1. Capital returns remain robust, with XOM deploying $9.2B on buybacks/dividends, HESM repurchasing $60M units/shares and hiking distributions 2.4% to $0.7792/share. Williams Companies (WMB) shows strong governance via AGM approvals (91-99% support). Non-energy filings like 13Fs and SPACs add neutral context but no sector impact. Overall, cost pressures challenge integrateds/midstream, but M&A catalysts and returns support resilience.

8 high priority 5 medium 13 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 04, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (May 4, 2026 period), dominant themes include aggressive M&A in industrial/REIT space (GNL-Modiv $535M all-stock deal, 4% AFFO accretive, 17% premium), mixed Q1 2026 earnings with pharma/biotech revenue growth averaging +7-8% YoY (Evolus +7%, Vertex +8%) offset by declines in offshore drilling (-13% QoQ Valaris) and telecom (-3.2% YoY Cogent), and robust capital allocation via buybacks/repurchases (Indivior $175M ASR, Progressive $467M treasury shares). Institutional 13Fs (14 filings) reveal heavy tech concentration (e.g., NVIDIA, Amazon top holdings across Yahav, Triglav, Montaka), signaling sustained bull market conviction. Forward-looking data flags lowered guidance (Norwegian Cruise Net Yield -3-5%, EPS $1.45-1.79) amid demand softness, contrasted by reaffirmed targets (Evolus $327-337M revenue). Bankruptcies (Safe & Green, Spirit Aviation wind-down) highlight distress in niche industrials/aviation. Portfolio-level trends: 6/12 earnings filings show YoY revenue growth >5% but 4/12 with EBITDA/affo declines; capital returns strong in 5 firms (dividends, buybacks up YoY). Actionable: M&A catalysts in Q3 2026, watch biotech data readouts H1-H2.

14 high priority 36 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 04, 2026

Across 50 filings in the S&P 500 Consumer Discretionary stream (with cross-sector exposure via REITs, food/retail, and industrials), sentiment is predominantly mixed (14/50), reflecting revenue growth averaging +12% YoY in 18 earnings reporters (e.g., Sterling +92%, L.B. Foster +24%, Tyson +4.4%) but offset by profitability challenges like impairments (Armada net loss worsened to $33.3M) and volume declines (FreightCar -33%, OneWater -8.5%). Guidance trends are resilient with 6 raises/reaffirmations (Armada FFO to $0.51-$0.55, Sterling EBITDA to $843-873M), signaling management conviction amid restructuring (e.g., Armada $562M portfolio sale, $700M debt paydown). Capital allocation favors shareholders via $24.1M buybacks (Armada), dividends (Tyson $0.48, Superior $0.14, SmartStop $1.60 annualized), and M&A approvals (Farmer Bros 86.9% yes). IPO activity (GMR, Liftoff, Fervo) and SPAC developments (Willow neutral, Flag Ship terminated) highlight deal flow risks/opportunities. Institutional 13Fs (11 filings) show stable heavy weighting in consumer/tech names like Costco, Amazon (e.g., Garrison top Costco $10M). Portfolio-level: Margin expansion in winners (Marzetti + to 23.6%) vs compression elsewhere; actionable now on raised guidance and near-term catalysts like May 15 Cushman redemption.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 04, 2026

Across 50 filings in the USA S&P 500 Healthcare stream (with broader financial crossovers), mixed sentiment dominates healthcare/biotech names, with 4/7 key players (Twist, Vertex, Merck, Aura) showing YoY revenue growth averaging +12.8% (Twist +19%, Vertex +8%, Merck +4.9%) but widening net losses due to elevated R&D/SG&A (e.g., Twist net loss +12% YoY to $44M, Merck $4.2B loss from $8.5B acquisition charge), signaling heavy investment in pipelines amid 99% revenue plunge outlier at Akston Biosciences IPO. Capital allocation leans bullish with buybacks surging (Intuitive Surgical $5B authorization, Tidewater $500M, New Mountain $66M YTD +$50M more, Aura $39M repurchase), dividends steady (CNA $0.48, Corebridge $0.25), and share repurchases reflecting management conviction despite NAV declines (New Mountain -5.2% to $10.92). Leadership transitions positive in healthcare (Aura new CEO Natalie Holles, Edwards new CFO Doretta Mistras), while non-healthcare finance/insurance shows stable NII but margin pressures (CNA combined ratio +380bps to 102.2%, Loews net income -9%). Forward guidance largely raised/reiterated (Twist FY26 rev to $442-447M +17-19% growth, Vertex $12.95-13.1B), building H2 2026-2027 catalysts like Aura Phase 3 topline. 13F filings (9 total) reveal neutral institutional positioning with heavy ETF/tech tilts but healthcare exposure (e.g., Thermo Fisher, UnitedHealth). Portfolio-level: Healthcare growth intact but loss-making (avg gross margin +100bps at Twist), buybacks signal undervaluation, watch M&A (Corebridge-Equitable, Rallybio termination fee $50M). Actionable: Favor buyback-heavy medtech/biotech over plunging revenue IPOs.

17 high priority 33 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 01, 2026

Across 31 filings from the USA S&P 500 Technology stream (broadly including adjacent sectors like telecom and software), Q1 2026 results show mixed performance with 12/17 quarterly reporters posting YoY revenue growth averaging +11% (led by Apple +16.5%, Cadence +19%, Iradimed +12.6-13%), but profitability pressures evident in 8/17 cases with net losses widening or income declining (e.g., Shentel net loss $15.8M vs $9.1M, Smurfit operating profit -54%). Acquisitions drove asset growth and cash burn in Cadence (-53% cash QoQ), Verizon (-56% cash QoQ), and Atmus (debt +$455M), while capital returns remained robust via buybacks (Apple $36B 6-mo, Verizon $2.5B Q1, Cadence $200M Q1) and dividends (Iradimed $0.20/sh, Atmus $0.055/sh). Forward guidance was largely reaffirmed (Shentel rev $370-377M, Iradimed FY $91-96M, Atmus sales $1.945-2.015B), but risks from restatements (Ducommun overstating NI $9.8M FY24) and workforce cuts (Shentel 10%) signal caution. Sentiment is mixed/neutral overall (20/31 mixed/neutral), with tech outliers like Apple and Cadence showing strength amid sector capex intensity. Portfolio-level trends point to revenue resilience but margin compression in 6/10 key filers (-150bps avg where reported) and ongoing M&A for growth.

17 high priority 14 medium 31 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 01, 2026

Across 30 filings from NASDAQ-100 related entities, Q1 2026 results reveal resilient revenue growth averaging 8.2% YoY (Apple +16.5%, Atmus +14.7%, Iradimed +12.6-13%, Verizon +2.9%, Shenandoah +4.8%), but profitability mixed with compressions in 6/12 reporters (Smurfit operating profit -54.2%, Shenandoah net loss widened to $15.8M from $9.1M, TXNM earnings -58.1%). Capital allocation remains shareholder-friendly with $36B Apple buybacks, $2.5B Verizon repurchases, steady dividends (Kennametal $0.20, Iradimed $0.20, Atmus $0.055), and gains from divestitures (First Community $10M pre-tax). M&A activity accelerates (Verizon $9.48B acquisitions boosting goodwill +34%, Atmus Koch Filter adding $456M net assets, TXNM Blackstone deal pending H2 2026 at $61.25/share). Risks emerge from accounting errors (Ducommun restatements overstating net income $9.8M FY2024), workforce cuts (Shenandoah 10% RIF saving $12.3M annually from 2027), and low AGM participation (Aditxt 34.17%). Forward guidance stable (Iradimed FY2026 rev $91-96M, Atmus $1.945-2.015B, Shenandoah $370-377M), signaling sector resilience amid macro pressures. Portfolio-level trend: Industrials/tech outperform telecom/energy on growth, with buybacks signaling management conviction.

13 high priority 17 medium 30 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 01, 2026

The 50 filings from S&P 500 Financials and adjacent sectors reveal mixed Q1 2026 results, with average revenue growth of +11% YoY across 25 reporting companies (e.g., Ares +strong fundraising, BNY Mellon +13%), but frequent margin compression (-100 bps avg in 8/15 industrials/financial services) and negative cash flows in 12 firms (e.g., Cinemark $(20.4)M op CF, Ryan Specialty $(167)M). Asset managers excelled with AUM/AUC/A growth averaging 15% YoY (Ares +18%, BNY +12% AUC/A, TPG $306B), driving fee income surges (+25% Ares), while banks/insurers showed resilient capital returns via dividends/buybacks totaling >$1B (News Corp $1B program, Verizon $2.5B repurchases). M&A activity heated up with 6 deals (UWM revised Two Harbors offer at $12 cash/2.33x, Esperion 58% premium acquisition, Stock Yards Field & Main), signaling consolidation. Capital allocation favors shareholders (18 firms: div hikes Piper +14%, buybacks Ryan $40M), but debt rises (Shenandoah +10%, Dream Finders +17% QoQ) and outflows (Virtus $(8.4)B) flag caution. Guidance mixed: 7 raises (Newell flat to +2%, Piper low-double digits), 3 cuts (Fulgent Non-GAAP loss to $(1.59)). Portfolio implication: Overweight asset managers/financial services on AUM tailwinds, underweight cyclicals amid cash burn; monitor Q2 catalysts like div record dates in June.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 01, 2026

Across 50 recent SEC filings from the S&P 500 Consumer Staples stream and related sectors, Q1 2026 results reveal mixed performance with average revenue growth of +4% YoY in staples-focused filers (e.g., Estee Lauder +5%, Colgate +8.4%, Newell -1.1%), driven by premium categories like fragrance and Latin America but offset by North America weakness and core sales declines. Margin trends show resilience with expansions in 4/7 key staples reporters (Estee Lauder +360 bps adjusted, Newell gross +100 bps) amid restructuring benefits, though Colgate saw -20 bps gross compression. Major M&A activity includes McCormick's $2B term loan for Unilever foods acquisition (Apollo), signaling consolidation in flavors/foods, while Estee Lauder pursues bolt-ons in India/UK skincare. Capital allocation leans shareholder-friendly with buybacks (Colgate $306M, Asbury $157M) and dividends (TPG $0.59, Perella $0.07), but cash burns in some (Newell -$233M op CF). Forward guidance largely positive (Estee FY26 organic high-end raise, Newell FY26 flat-2% sales), building a catalyst calendar into Q2 earnings. Broader patterns flag staples outperformance vs. autos/telecom declines, with institutional 13Fs showing staples exposure via ETFs/dividend funds. Actionable implication: Favor premium staples with China exposure and M&A; monitor NA softness.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — May 01, 2026

The 50 filings reveal mixed Q1 2026 performance across S&P 500 Industrials and adjacent sectors, with 14/22 Q1 reporters showing YoY revenue growth averaging +6.2% (e.g., Cboe +29%, Zeta +49.9%, Parker-Hannifin +8.3%), but 8 experiencing declines averaging -15.4% (e.g., Wabash -20.4%, Matthews -39.5%, Dream Finders -10.3%), driven by transportation softening and divestitures. EBITDA and operating income trends are bifurcated: 9 companies grew EBITDA/Adj EBITDA +15% avg (Shentel +15%, Ares record highs), while margins compressed -120 bps avg in 7/15 cases amid restructuring and capex. Capital allocation shines with $2.5B Verizon repurchases, $214M C.H. Robinson buybacks, $40M Fulgent repurchases, and dividend declarations/increases (Ares $1.35, Federal Realty $1.13 up from $1.10). M&A/refinancing activity bullish: Herbalife $45M annual interest savings, UWM revised Two Harbors offer, Stock Yards acquisition adding branches. Guidance mostly stable/reiterated (Shentel $370-377M rev), with raises (Cboe low double-digits to mid-teens, Federal Realty FFO $7.46-7.55). 13F filings (12/50) show neutral institutional positioning tilted to tech/ETFs over pure industrials, with GE holding Beta Technologies/Hyliion. Implications: Cyclical industrials stabilizing via backlogs (Wabash +$132M), but watch transportation losses; prioritize capital returners for near-term alpha.

22 high priority 28 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 01, 2026

S&P 500 Energy sector filings reveal mixed Q1 2026 results for majors ExxonMobil and Chevron, with GAAP earnings declining sharply YoY (XOM -46%, CVX from $3.5B to $2.2B) due to timing effects, legal reserves, and downstream losses, but offset by strong production growth (CVX worldwide +15% to 3,858 MBOED, US +24% to 2,024 MBOED; XOM record Guyana output) and robust shareholder returns (XOM $9.2B distributions incl. $4.9B buybacks; CVX $6.0B incl. $2.5B repurchases). Marathon Petroleum's annual meeting approved directors, auditor, and exec comp but rejected governance reforms needing 80% votes, signaling entrenched board structure. Robert Half (non-energy outlier) shows sharp declines (revenues -3.8% YoY, net income -20.5% YoY). Portfolio-level trends include upstream strength vs. downstream weakness, sustained capital returns amid earnings volatility, and capex guidance stability at XOM ($27-29B FY2026). Implications: Favor production-focused longs, monitor downstream recovery; governance stasis at MPC may cap upside.

1 high priority 3 medium 4 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 01, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (primarily Q1 2026 earnings, 8-Ks, and proxies), a dominant theme is robust revenue growth averaging 15-20% YoY in 18/22 reporting companies (e.g., Cboe +29%, Oppenheimer +21%, Ryan Specialty +15%), driven by investment banking, data services, and M&A, though profitability remains mixed due to one-offs like legal accruals ($70M at Oppenheimer), restructuring (10% workforce cuts at Shenandoah, Cboe), and margin compression (-20bps at Colgate). Capital allocation trends are shareholder-friendly with 7 companies raising dividends (Oppenheimer +11%, TPG $0.59/share) and active buybacks (Verizon $2.5B Q1, Cboe $45M Q1, Ryan $40M Q1), signaling management conviction amid AUM/AUC growth (BNY Mellon +12% AUC/A to $59.4T). M&A activity accelerates (UWM revised Two Harbors offer, Stock Yards/Field & Main close, Burke & Herbert/LINKBANCORP), while refinancings lower costs (Herbalife $45M annual savings). Guidance changes lean positive (Cboe raised organic revenue to mid-teens, Civeo revenue to $675-700M), but telecom/industrials show declines (Wabash sales -20% YoY, Shenandoah net loss widened). Portfolio-level: Financials outperform (avg +18% rev YoY vs industrials +5%), with Nasdaq compliance resolutions (Soluna, Onfolio) adding stability; overall sentiment mixed but actionably bullish on efficiency gains and catalysts.

26 high priority 24 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 01, 2026

Across 50 SEC filings from the USA S&P 500 Consumer Discretionary stream (broadly including adjacent financials, industrials, and REITs), Q1 2026 results reveal mixed performance with average revenue growth of ~11% YoY among 18 reporting firms (e.g., Cboe +29%, Cinemark +19%, Boston Scientific +12%), but 10/18 showed profitability declines averaging -35% YoY due to margin compression (-150 bps avg in 7 cases) and rising costs. Capital allocation remains shareholder-friendly, with buybacks totaling >$150M (Fulgent $40M, Cboe $73M incl. plans, CubeSmart $33M) and dividend increases (Federal Realty +3%, BNY Mellon steady 24% payout). Guidance changes are net positive: raises at Cboe (organic revenue to mid-teens), Federal Realty (FFO $7.46-$7.55), lowered expenses at Cboe/Smurfit offsets. M&A/refinancing activity boosts flexibility (Herbalife $45M annual savings, Burke & Herbert merger to 100 branches), while 12 13F filings highlight institutional conviction in consumer staples/tech proxies like Yum China ($555M BLS), Walmart ($64M FourPath). Cash flow trends weak (9/15 negative OCF), signaling near-term risks amid workforce cuts (Cboe -20%) and compliance issues (Greenidge Nasdaq). Portfolio-level: outperformance in exchanges/REITs vs. homebuilders/packaging underperformance, with catalysts from earnings calls and mergers.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 01, 2026

Across the 50 filings in the USA S&P 500 Healthcare intelligence stream (with diverse sector exposure including financials, biotech, and industrials), Q1 2026 results reveal robust revenue growth averaging +40% YoY in reporting companies (e.g., Moderna +260%, SCI Engineered +133%, Cinemark +18.9%), but persistent negative operating cash flows in 8/15 Q1 filers (avg -$100M, e.g., Ryan -$167M, Cinemark -$20M) signal working capital strains despite margin improvements in 6 cases (e.g., Newell gross margin +100 bps to 33.1%). Capital allocation leans shareholder-friendly with buybacks totaling >$200M (Ryan $40M, Civeo $14M, Virtu $56M, Truist $1.1B shares) and steady dividends (BNY 24% payout, Alerus +5% to $0.21), while M&A activity (Boston Scientific Nalu $588M, Burke & Herbert merger) bolsters healthcare and financial footprints. Healthcare standouts like Boston Scientific (+11.6% sales YoY, +99% net income) and Moderna (+260% revenue) contrast mixed sentiment (12/20 mixed), with forward guidance raises in Newell (FY sales flat to +2%) and Civeo (FY rev $675-700M) providing near-term catalysts amid insider-agnostic filings. Portfolio-level trends show financials outperforming (avg net income +40% YoY in banks like Glacier +50.5%, Truist +17%) vs. consumer/industrials cash burn risks, implying rotation opportunities into growth healthcare names. Overall, bullish growth momentum tempers by liquidity concerns, favoring buyback-heavy firms with raised guidance.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 30, 2026

Across 45 filings dominated by Q1 2026 results and institutional 13Fs, S&P 500 Technology peers like Apple and KLA showcased robust growth with Apple posting record Q2 FY2026 revenue of $111.2B (+17% YoY) and Services +16% YoY, while KLA reported Q3 FY2026 revenue +11.5% YoY to $3.4B; however, broader filings reveal mixed sector trends with average revenue growth ~8-10% YoY in reporting companies but frequent margin compressions (e.g., -270bps at BMS, -2.4% NIM at NorthEast). Institutional 13Fs from Munich Re ($4B portfolio top NVDA/MSFT), Arista Wealth (AAPL/SPY heavy), and others confirm sustained overweight in mega-cap tech amid diversified holdings. Capital allocation trends favor shareholders with Apple's +4% dividend hike to $0.27/share and $100B buyback authorization, KLA's $1.72B repurchases, First Northern's 5% stock dividend +6% repurchase, and multiple quarterly dividends (e.g., Esquire $0.20/share). Forward guidance largely stable or upbeat (Weave FY rev $275-278M, Smurfit EBITDA $5-5.3B reaffirmed), but outliers like NCS Multistage's net loss signal caution. Portfolio-level: 7/12 growth reporters beat YoY revenue (avg +12%), but 6/10 saw margin/FFO declines; tech outliers outperform with ROE/ROA strength. Key implication: Favor tech leaders amid capital returns surge, monitor June AGMs for governance catalysts.

17 high priority 28 medium 45 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 30, 2026

Across 50 SEC filings from NASDAQ-100 constituents and related entities for the period ending April 30, 2026, Q1 2026 results reveal robust revenue growth in megacap tech (Amazon +16.6% YoY, Alphabet +21.8% YoY, Meta +33.1% YoY, Apple +17% YoY) averaging 22% YoY, offsetting margin pressures and declines in industrials/healthcare (Acadia NI -51% YoY, CPKC rev -2% YoY, Smurfit NI -83.5% YoY). Capital allocation trends emphasize shareholder returns with aggressive buybacks (CCC $400M, CPKC $680M Q1, Apple +$100B authorization) and dividends (Apple +4%, First Northern 5% stock div), alongside biotech fundraising (Intellia $194.6M extending runway to 2028, Immunic $200M). Mixed sentiment dominates (24/50 filings), driven by strong top-line but capex surges (Meta +46.7% YoY, Amazon +76.7% YoY) and exec changes (CCC CFO departure, PayPal reorg). Forward-looking catalysts cluster in June (10+ annual meetings, e.g., ImmunityBio June 9, Intellia June 9) and H2 2026 (Phase 3 data, approvals). Institutional 13G/13F filings confirm passive stakes in tech leaders (Vanguard 7.49% NFLX, 7.48% MSFT, 5.61% TSLA), signaling stability. Portfolio-level trends show 12/18 reporting companies with YoY revenue growth >10%, but 7/12 with EBITDA/operating margin contraction averaging -200bps, highlighting investment phase risks/opportunities.

18 high priority 32 medium 50 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 30, 2026

Across 50 filings from the USA S&P 500 Financials stream (including banks, insurers, asset managers, and related), Q1 2026 quarterly reports dominate with 70% showing revenue growth averaging +11% YoY (e.g., Hippo +10%, Southside NII +7.1%, First Northern NII +7.9%), but profitability is mixed as 55% reported net income declines or losses due to opex surges (avg +20% YoY), impairments, and margin compression (e.g., Pilgrim's EBITDA margin -520 bps to 6.8%). Financial institutions like banks (First Northern NI +61% YoY, Southside +8%) and insurers (Hippo turnaround to $7.1M NI from -$47.7M loss, Cigna adj inc +12%) outperform non-financial outliers, signaling sector resilience amid deposit softness and NIM stability. Capital allocation remains shareholder-friendly with buybacks (e.g., Southside authorized 6%, Moelis $117M) and dividends (e.g., First Northern 5% stock dividend), though cash flows weaken QoQ in 60% of cases (avg -15%). Forward-looking guidance is raised in key names (Hippo GWP to $1.45-1.525B, Cigna FY adj EPS $30.35+), building a positive catalyst calendar into H2 2026. Portfolio-level trends highlight relative outperformance in regional banks (ROAA avg 1.2% up YoY) vs broader pressures from impairments and capex, implying tactical overweight in profitable financials with strong liquidity (net leverage <2x). Overall sentiment mixed (65% of filings), with actionable alpha in insurer turnarounds and bank deposit betas.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 30, 2026

Across 50 SEC filings from the USA S&P 500 Consumer Staples stream (broadly including adjacent sectors like food/beverages, household products, and related), Q1 2026 results reveal robust revenue growth averaging +25% YoY in 12/18 reporting companies (e.g., Angel Studios +143%, Eli Lilly +56%, Glaukos +41%), driven by pricing power and volume in select areas, though staples volumes declined (Molson Coors -2.9%, Altria cigarettes -2.4% adjusted, Hershey -2 points). Margin trends mixed with expansions in 7/15 (e.g., Angel +300bps to 62%, Iron Mountain +20bps to 36.6%) offset by compressions (Hershey salty snacks -530bps, UMC -590bps gross). Capital returns strong via buybacks ($2.4B aggregate noted, e.g., CCC $400M, Altria $280M) and dividends (Altria $1.8B, Hershey reaffirmed), but cash piles declined QoQ in 10/15 (avg -20%). Guidance raised in 6 key names (Eli Lilly rev to $82-85B, Iron Mountain EBITDA +14%, Garrett sales to $3.6-3.9B), signaling conviction amid mixed sentiment (14/20 mixed). Portfolio-level theme: Pricing offsets volume weakness in staples; watch biotech/health adjacents for outsized growth. Critical implication: Favor raised-guidance leaders for near-term upside, hedge volume risks in beverages/tobacco.

20 high priority 30 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 30, 2026

Across 50 SEC filings from S&P 500 Industrials and adjacent sectors for Q1 2026 (period ending ~March 31, 2026), mixed sentiment prevails in 70% of material reports, with 18/25 key quarterly earners showing average revenue growth of 12% YoY (range -30% to +27%) but margin compression in 14 cases averaging -150 bps YoY due to cost inflation, impairments, and weather disruptions. Industrials like Caterpillar (+22% sales), Trane Technologies (+6% revenues, record backlog +30%), and L3Harris (+12% revenue, backlog $40.7B) highlight robust demand in construction, HVAC, and defense, offset by softer Resource Industries and EMEA. Capital allocation trends strongly favor shareholders with $12B+ in buybacks/dividends across 15 firms (e.g., Caterpillar $5B, Newmark 10.4M shares), while M&A activity surges (e.g., Pioneer Bancorp acquisitions, Martin Marietta New Frontier deal). Guidance raised in 9 companies (e.g., Trane to 9.5% growth, L3Harris EPS +$0.10), signaling conviction amid geopolitical risks. Banks exhibit NIM stability (avg +5 bps QoQ) but deposit/loan volatility; non-industrials like Alphabet (+22% revenue) provide relative outperformance benchmarks. Portfolio implication: overweight defensive industrials with strong backlogs/book-to-bills >1.2x, monitor margin recovery catalysts.

12 high priority 38 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 30, 2026

Across 20 SEC filings from the USA S&P 500 Energy stream (including contextual non-energy for completeness), Q1 2026 results show mixed performance with average revenue growth of ~14% YoY where reported (Valero +7%, CommScope +21.6%, SunCoke +4%, Southern Copper +36.2%, offset by ConocoPhillips -5%), but profitability trends divergent: strong turnarounds (Valero from loss to $1.26B NI) contrasted by declines (Conoco NI -23%, SunCoke op inc -85%). Capital allocation remains shareholder-friendly, with $ billions returned via dividends/buybacks (Conoco $2B Q1, Valero $923M Q1 treasury+div, CommScope $10/share special dist). M&A/divestitures drive gains (CommScope $5.3B discontinued ops gain from CCS sale, RUCKUS to Belden $1.846B; SunCoke Phoenix acquisition adding $63M rev). Energy sector faces production headwinds (Conoco -3% YoY to 2.3MMBOED, Ecopetrol slight dip) but stable guidance (SunCoke FY adj EBITDA $230-250M reaffirmed, Conoco FY prod 2.295-2.325MMBOED). Sentiment mixed overall (9/20 mixed), with outliers in refining/metals shining; portfolio implication: favor capital returners amid volatile ops metrics.

10 high priority 10 medium 20 total filings